Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rachel G. Gross is active.

Publication


Featured researches published by Rachel G. Gross.


Annals of Neurology | 2011

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

Alice Chen-Plotkin; William T. Hu; Andrew Siderowf; Daniel Weintraub; Rachel G. Gross; Howard I. Hurtig; Sharon X. Xie; Steven E. Arnold; Murray Grossman; Christopher M. Clark; Leslie M. Shaw; Leo McCluskey; Lauren Elman; Vivianna M. Van Deerlin; Virginia M.-Y. Lee; Holly Soares; John Q. Trojanowski

Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma‐based biomarkers for CI in PD.


Nature Communications | 2015

Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy

Naomi Kouri; Owen A. Ross; Beth A. Dombroski; Curtis S. Younkin; Daniel J. Serie; Alexandra I. Soto-Ortolaza; Matt Baker; Ni Cole A. Finch; Hyejin Yoon; Jungsu Kim; Shinsuke Fujioka; Catriona McLean; Bernardino Ghetti; Salvatore Spina; Laura B. Cantwell; Martin R. Farlow; Jordan Grafman; Edward D. Huey; Mi Ryung Han; Sherry Beecher; Evan T. Geller; Hans A. Kretzschmar; Sigrun Roeber; Marla Gearing; Jorge L. Juncos; Jean Paul Vonsattel; Vivianna M. Van Deerlin; Murray Grossman; Howard I. Hurtig; Rachel G. Gross

Corticobasal degeneration (CBD) is a neurodegenerative disorder affecting movement and cognition, definitively diagnosed only at autopsy. Here, we conduct a genome-wide association study (GWAS) in CBD cases (n=152) and 3,311 controls, and 67 CBD cases and 439 controls in a replication stage. Associations with meta-analysis were 17q21 at MAPT (P=1.42 × 10−12), 8p12 at lnc-KIF13B-1, a long non-coding RNA (rs643472; P=3.41 × 10−8), and 2p22 at SOS1 (rs963731; P=1.76 × 10−7). Testing for association of CBD with top progressive supranuclear palsy (PSP) GWAS single-nucleotide polymorphisms (SNPs) identified associations at MOBP (3p22; rs1768208; P=2.07 × 10−7) and MAPT H1c (17q21; rs242557; P=7.91 × 10−6). We previously reported SNP/transcript level associations with rs8070723/MAPT, rs242557/MAPT, and rs1768208/MOBP and herein identified association with rs963731/SOS1. We identify new CBD susceptibility loci and show that CBD and PSP share a genetic risk factor other than MAPT at 3p22 MOBP (myelin-associated oligodendrocyte basic protein).


Alzheimers & Dementia | 2014

A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank

Jon B. Toledo; Vivianna M. Van Deerlin; Edward B. Lee; EunRan Suh; Young Min Baek; John L. Robinson; Sharon X. Xie; Jennifer McBride; Elisabeth McCarty Wood; Theresa Schuck; David J. Irwin; Rachel G. Gross; Howard I. Hurtig; Leo McCluskey; Lauren Elman; Jason Karlawish; Gerard D. Schellenberg; Alice Chen-Plotkin; David A. Wolk; Murray Grossman; Steven E. Arnold; Leslie M. Shaw; Virginia M.-Y. Lee; John Q. Trojanowski

Neurodegenerative diseases (NDs) are defined by the accumulation of abnormal protein deposits in the central nervous system (CNS), and only neuropathological examination enables a definitive diagnosis. Brain banks and their associated scientific programs have shaped the actual knowledge of NDs, identifying and characterizing the CNS deposits that define new diseases, formulating staging schemes, and establishing correlations between neuropathological changes and clinical features. However, brain banks have evolved to accommodate the banking of biofluids as well as DNA and RNA samples. Moreover, the value of biobanks is greatly enhanced if they link all the multidimensional clinical and laboratory information of each case, which is accomplished, optimally, using systematic and standardized operating procedures, and in the framework of multidisciplinary teams with the support of a flexible and user‐friendly database system that facilitates the sharing of information of all the teams in the network. We describe a biobanking system that is a platform for discovery research at the Center for Neurodegenerative Disease Research at the University of Pennsylvania.


Neurosignals | 2008

Cognitive Impairment in Parkinson's Disease and Dementia with Lewy Bodies: A Spectrum of Disease

Rachel G. Gross; Andrew Siderowf; Howard I. Hurtig

Parkinson’s disease (PD) is classically thought of as a movement disorder characterized by tremor, rigidity and postural instability. Nevertheless, there is growing recognition of prominent cognitive impairment in PD and related disorders, which is responsible for substantial disability in these patients. This review will focus on cognitive impairment associated with Lewy body pathology, including PD with dementia (PDD) and dementia with Lewy bodies (DLB). We will review the epidemiology, clinical evaluation, underlying mechanisms and treatment of cognitive impairment in these patients. Despite differences between PDD and DLB, there is clinical, neuropathological and radiological overlap between these disorders, supporting the view that they represent a spectrum of disease. These observations suggest that common targets for diagnosis and treatment of these disorders can be identified.


NeuroImage | 2014

Sparse canonical correlation analysis relates network-level atrophy to multivariate cognitive measures in a neurodegenerative population

Brian B. Avants; David J. Libon; Katya Rascovsky; Ashley Boller; Corey T. McMillan; Lauren Massimo; H. Branch Coslett; Anjan Chatterjee; Rachel G. Gross; Murray Grossman

This study establishes that sparse canonical correlation analysis (SCCAN) identifies generalizable, structural MRI-derived cortical networks that relate to five distinct categories of cognition. We obtain multivariate psychometrics from the domain-specific sub-scales of the Philadelphia Brief Assessment of Cognition (PBAC). By using a training and separate testing stage, we find that PBAC-defined cognitive domains of language, visuospatial functioning, episodic memory, executive control, and social functioning correlate with unique and distributed areas of gray matter (GM). In contrast, a parallel univariate framework fails to identify, from the training data, regions that are also significant in the left-out test dataset. The cohort includes164 patients with Alzheimers disease, behavioral-variant frontotemporal dementia, semantic variant primary progressive aphasia, non-fluent/agrammatic primary progressive aphasia, or corticobasal syndrome. The analysis is implemented with open-source software for which we provide examples in the text. In conclusion, we show that multivariate techniques identify biologically-plausible brain regions supporting specific cognitive domains. The findings are identified in training data and confirmed in test data.


Clinical Neuropsychologist | 2011

The Philadelphia Brief Assessment of Cognition (PBAC): a validated screening measure for dementia.

David J. Libon; Katya Rascovsky; Rachel G. Gross; Matthew T. White; Sharon X. Xie; Michael Dreyfuss; Ashley Boller; Lauren Massimo; Peachie Moore; Jessica Kitain; H. Branch Coslett; Anjan Chatterjee; Murray Grossman

The Philadelphia Brief Assessment of the Cognition (PBAC) is a brief dementia-screening instrument. The PBAC assesses five cognitive domains: working memory/executive control; lexical retrieval/language; visuospatial/visuoconstructional operations; verbal/visual episodic memory; and behavior/social comportment. A revised version of the PBAC was administered to 198 participants including patients with Alzheimers disease (AD) (n = 46) and four groups of patients with frontotemporal dementia (FTD) syndromes: behavioral-variant FTD (bvFTD; n = 65), semantic-variant primary progressive aphasia (PPA) (svPPA; n = 22), non-fluent/agrammatic-variant PPA (nfaPPA; n = 23), and corticobasal syndrome (CBS; n = 42), and a group of normal controls (n = 15). The total PBAC score was highly correlated with the MMSE. The criterion validity of the PBAC was assessed relative to standard neuropsychological test performance. Using standard neuropsychological test performance as a criterion, the total PBAC score accurately identified the presence and severity of dementia. Intra-class correlations between PBAC subscales and standard neuropsychological tests were highly significant. PBAC subscales demonstrated good clinical utility in distinguishing AD and FTD subtypes using receiver operating characteristic analysis and standard diagnostic performance statistics to determine optimal subscale cut scores. The PBAC is a valid tool and able to assesses differential patterns neuropsychological/behavioral impairment in a broad range of neurodegenerative conditions.


Brain and Language | 2011

The organization of narrative discourse in Lewy body spectrum disorder

Sharon Ash; Corey T. McMillan; Rachel G. Gross; Philip A. Cook; Brianna Morgan; Ashley Boller; Michael Dreyfuss; Andrew Siderowf; Murray Grossman

Narrative discourse is an essential component of day-to-day communication, but little is known about narrative in Lewy body spectrum disorder (LBSD), including Parkinsons disease (PD), Parkinsons disease with dementia (PDD), and dementia with Lewy bodies (DLB). We performed a detailed analysis of a semi-structured speech sample in 32 non-aphasic patients with LBSD, and we related their narrative impairments to gray matter (GM) atrophy using voxel-based morphometry. We found that patients with PDD and DLB have significant difficulty organizing their narrative speech. This was correlated with deficits on measures of executive functioning and speech fluency. Regression analyses associated this deficit with reduced cortical volume in inferior frontal and anterior cingulate regions. These findings are consistent with a model of narrative discourse that includes executive as well as language components and with an impairment of the organizational component of narrative discourse in patients with PDD and DLB.


Brain and Language | 2012

Impairments of Speech Fluency in Lewy Body Spectrum Disorder.

Sharon Ash; Corey T. McMillan; Rachel G. Gross; Philip A. Cook; Delani Gunawardena; Brianna Morgan; Ashley Boller; Andrew Siderowf; Murray Grossman

Few studies have examined connected speech in demented and non-demented patients with Parkinsons disease (PD). We assessed the speech production of 35 patients with Lewy body spectrum disorder (LBSD), including non-demented PD patients, patients with PD dementia (PDD), and patients with dementia with Lewy bodies (DLB), in a semi-structured narrative speech sample in order to characterize impairments of speech fluency and to determine the factors contributing to reduced speech fluency in these patients. Both demented and non-demented PD patients exhibited reduced speech fluency, characterized by reduced overall speech rate and long pauses between sentences. Reduced speech rate in LBSD correlated with measures of between-utterance pauses, executive functioning, and grammatical comprehension. Regression analyses related non-fluent speech, grammatical difficulty, and executive difficulty to atrophy in frontal brain regions. These findings indicate that multiple factors contribute to slowed speech in LBSD, and this is mediated in part by disease in frontal brain regions.


Neurology: Clinical Practice | 2014

Corticobasal syndrome Five new things

Lama M. Chahine; Tanya Rebeiz; Jean J. Rebeiz; Murray Grossman; Rachel G. Gross

Corticobasal syndrome (CBS) is characterized by asymmetric involuntary movements including rigidity, tremor, dystonia, and myoclonus, and often associated with apraxia, cortical sensory deficits, and alien limb phenomena. Additionally, there are various nonmotor (cognitive and language) deficits. CBS is associated with several distinct histopathologies, including corticobasal degeneration, other forms of tau-related frontotemporal lobar degeneration such as progressive supranuclear palsy, and Alzheimer disease. Accurate antemortem diagnosis of underlying pathology in CBS is challenging, though certain clinical and imaging findings may be helpful. Five recent advances in the understanding of CBS are reviewed, including clinical and pathologic features, imaging and CSF biomarkers, the role of specific genes, and the concept of a spectrum of tauopathies.


Frontiers in Psychology | 2013

Converging Evidence for the Processing Costs Associated with Ambiguous Quantifier Comprehension

Corey T. McMillan; Danielle Coleman; Robin Clark; Tsao-Wei Liang; Rachel G. Gross; Murray Grossman

Traditional neuroanatomic models of language comprehension have emphasized a core language network situated in peri-Sylvian cortex. More recent evidence appears to extend the neuroanatomic network beyond peri-Sylvian cortex to encompass other aspects of sentence processing. In this study, we evaluate the neuroanatomic basis for processing the ambiguity in doubly-quantified sentences. For example, a sentence like “All the dogs jumped in a lake” can be interpreted with a collective interpretation (e.g., several dogs jumping into a single lake) or a distributive interpretation (e.g., several dogs each jumping into a different lake). In Experiment 1, we used BOLD fMRI to investigate neuroanatomic recruitment by young adults during the interpretation of ambiguous doubly-quantified sentences in a sentence-picture verification task. We observed that young adults exhibited a processing cost associated with interpreting ambiguous sentences and this was related to frontal and parietal cortex recruitment. In Experiment 2, we investigate ambiguous sentence processing with the identical materials in non-aphasic patients with behavioral variant frontotemporal dementia (bvFTD) who have frontal cortex disease and executive and decision-making limitations. bvFTD patients are insensitive to ambiguity associated with doubly-quantified sentences, and this is related to the magnitude of their frontal cortex disease. These studies provide converging evidence that cortical regions that extend beyond peri-Sylvian cortex help support the processing costs associated with the interpretation of ambiguous doubly-quantified sentences.

Collaboration


Dive into the Rachel G. Gross's collaboration.

Top Co-Authors

Avatar

Murray Grossman

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Andrew Siderowf

Avid Radiopharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Howard I. Hurtig

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Corey T. McMillan

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Daniel Weintraub

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael Dreyfuss

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Ashley Boller

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Jacqueline Rick

University of Pennsylvania

View shared research outputs
Researchain Logo
Decentralizing Knowledge